Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Study of BTK Inhibitor DTRMWXHS-12 in B-Cell Lymphoma
NCT02891590Phase 1Completed
- Sponsor
- DTRM Biopharma
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Multivalent & Scaffold-Based Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DTRMWXHS-12 in B cell lymphoma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and 2 more, sponsored by DTRM Biopharma. Primary endpoint: Number of participants with adverse events. Started Sep 2016; status: completed.
02
Drugs
DTRMWXHS-12
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02891590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891590.